U.S. Markets close in 1 hr 29 mins

Kronos Bio, Inc. (KRON)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.59-0.51 (-1.54%)
As of 2:31PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close33.10
Bid32.10 x 1200
Ask32.21 x 1100
Day's Range30.11 - 33.50
52 Week Range25.50 - 34.90
Avg. Volume1,229,400
Market Cap1.793B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the closing of its previously announced initial public offering of 15,131,579 shares of its common stock, which includes 1,973,684 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Kronos Bio from the offering were approximately $287.5 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on October 9, 2020, under the ticker symbol “KRON.” Goldman Sachs & Co. LLC, Jefferies, Cowen and Piper Sandler acted as joint book-running managers for the offering.A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on October 8, 2020. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. The offering was made only by means of a written prospectus, forming a part of the effective registration statement. A copy of the final prospectus relating to the initial public offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at 866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at prospectus@psc.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Kronos Bio, Inc. Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. The company has headquarters in San Mateo, Calif., and a research facility in Cambridge, Mass.Contact: Stephanie Yao Executive Director, Investor Relations and Corporate Communications 650-502-6605 media@kronosbio.com

  • Barrons.com

    Kronos, the Latest Biotech IPO, Soars 58%

    Kronos is one of three biotechs—including Shattuck Labs and Spruce Biosciences—that made their market debuts Friday.

  • Barrons.com

    Shattuck Labs Surges in Market Debut Amid Flurry of IPOs

    Shares of (STTK) soared nearly 35% as a flurry of biotechs and a Chinese edutainment company went public on Friday. Shattuck’s stock opened at $22.10 and hit a high of $22.90. The solid debut comes after Shattuck Labs (ticker: STTK) increased the size of its deal on Thursday, according to a statement.